# Serum selenium levels and subacute thyroiditis: associations with disease course and long-term outcomes in a case-control study

**Authors:** Davut Sakız, Murat Çalapkulu, Muhammed Erkam Sencar, İlknur Öztürk Ünsal, Sema Hepşen, Hayri Bostan, Bekir Uçan, Erman Çakal

PMC · DOI: 10.1186/s12902-025-01903-6 · BMC Endocrine Disorders · 2025-03-18

## TL;DR

This study found no significant difference in selenium levels between people with subacute thyroiditis and healthy controls, though lower selenium may be linked to more severe symptoms.

## Contribution

The study is the first to investigate the relationship between serum selenium levels and long-term outcomes in subacute thyroiditis.

## Key findings

- Serum selenium levels did not significantly differ between SAT patients and healthy controls.
- Lower selenium levels were associated with more severe disease symptoms like higher pain and inflammation markers.
- Selenium levels had no significant impact on long-term outcomes like recurrence or hypothyroidism.

## Abstract

Subacute thyroiditis (SAT) is an inflammatory disease that induces thyrotoxicosis. Selenium is an essential trace element in thyroid physiology, which has anti-inflammatory and antioxidant properties. However, the relationship between serum selenium levels and SAT has not been well studied. The objective of this study was to evaluate serum selenium levels in patients with SAT compared to healthy controls and to investigate potential correlations between selenium status and clinical outcomes, including disease severity, delayed remission, recurrence, and the development of permanent hypothyroidism.

This case-control study included 59 patients with SAT and 50 healthy control subjects. Serum selenium levels were analysed using inductively coupled plasma mass spectrometry.

The serum selenium levels of patients with SAT were 69.10 (24.60–130.20) µg/L, while those of the control group were 64.20 (39.21–106.80) µg/L (p = 0.121). A negative correlation was detected between serum selenium levels and erythrocyte sedimentation rate, C-reactive protein, neutrophil-to-lymphocyte ratio, free thyroxine, and pain severity. Serum selenium levels did not significantly differ in terms of the response to initial treatment, recurrence, and permanent hypothyroidism.

The study results showed no significant difference in serum selenium levels between patients with SAT and the control group. These results suggest that although lower serum selenium levels may be associated with a more severe and painful SAT course, there is no impact on the long-term prognosis.

## Linked entities

- **Chemicals:** selenium (PubChem CID 6326970)
- **Diseases:** subacute thyroiditis (MONDO:0006982), thyrotoxicosis (MONDO:0010138), hypothyroidism (MONDO:0005420)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** thyrotoxicosis (MESH:C566386), pain (MESH:D010146), inflammatory (MESH:D007249), SAT (MESH:D013968), hypothyroidism (MESH:D007037)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11916927/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC11916927/full.md

---
Source: https://tomesphere.com/paper/PMC11916927